Premium Only Content
This video is only available to Rumble Premium subscribers. Subscribe to
enjoy exclusive content and ad-free viewing.

We believe the risk-benefit profile for our Alzheimer’s drug is acceptable, says Eisai U.S. CEO
2 years ago
2
Ivan Cheung, Eisai U.S. CEO, joins ‘Closing Bell’ to discuss the results of Eisai’s experimental Alzheimer’s phase three trial, the side effects associated with the Alzheimer’s drug and more.
Loading comments...
-
LIVE
Badlands Media
7 hours agoBadlands Daily - July 8, 2025
4,921 watching -
1:09:55
Dear America
3 hours agoIT’S ALL A COVER-UP!! Don’t Be FOOLED!! + LA Mayor Tries To STOP ICE Raids!!
90.3K95 -
LIVE
The Big Mig™
2 hours agoIran Bounty On Trump Grows To $30 Million
5,249 watching -
LIVE
Matt Kohrs
10 hours agoTurnaround Tuesday 🚀🚀🚀 || Live Trading Options & Futures
680 watching -
LIVE
Wendy Bell Radio
6 hours agoNothing To See Here
9,319 watching -
The Mike Schwartz Show
2 hours agoTHE MIKE SCHWARTZ SHOW with DR. MICHAEL J SCHWARTZ 07-08-2025
4.6K -
1:04:24
Game On!
14 hours ago $4.47 earnedThe NFL is CONSPIRING to Keep The Kansas City Chiefs OUT OF THE Playoffs!
30.3K8 -
2:03:16
AP4Liberty
14 hours ago $2.46 earnedThey Said the Epstein List Existed—Then THIS Happened in the White House
17.6K10 -
LIVE
PudgeTV
12 hours ago🟠 Witcher 3: The Wild Hunt | Day 6 - This Game is HARD!!!
290 watching -
19:34
BlackBeltBarrister
22 hours ago $2.61 earnedWhy People Say it's Two Tier Policing
29.9K19